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Abstract: Few studies have investigated the significance of decreased FEV1 in non-COPD, 
nonasthmatic healthy subjects. We hypothesized that a lower FEV1 in these subjects is a potential 
marker of an increased susceptibility to obstructive lung disease such as asthma and COPD. 
This was a cross-sectional analysis of 1505 Japanese adults. We divided the population of 
healthy adults with no respiratory diseases whose FEV1/FVC ratio was $70% (n = 1369) 
into 2 groups according to their prebronchodilator FEV1 (% predicted) measurements: ,80% 
(n = 217) and $80% (n = 1152). We compared clinical data – including gender, age,   smoking 
habits, total IgE levels, and annual decline of FEV1 – between these 2 groups. In addition, 
as our group recently found that TSLP variants are associated with asthma and reduced lung 
function, we assessed whether TSLP single nucleotide polymorphisms (SNPs) were associated 
with baseline lung function in non-COPD, nonasthmatic healthy subjects (n = 1368). Although 
about half of the subjects with lower FEV1 had never smoked, smoking was the main risk fac-
tor for the decreased FEV1 in non-COPD, nonasthmatic subjects. However, the subjects with 
lower FEV1 had a significantly higher annual decline in FEV1 independent of smoking status. 
Airflow obstruction was associated with increased levels of total serum IgE (P = 0.029) and 
with 2 functional TSLP SNPs (corrected P = 0.027–0.058 for FEV1% predicted, corrected 
P = 0.015–0.033 for FEV1/FVC). This study highlights the importance of early recognition of 
a decreased FEV1 in healthy subjects without evident pulmonary diseases because it predicts 
a rapid decline in FEV1 irrespective of smoking status. Our series of studies identified TSLP 
variants as a potential susceptibility locus to asthma and to lower lung function in non-COPD, 
nonasthmatic healthy subjects, which may support the contention that genetic determinants of 
lung function influence susceptibility to asthma.
Keywords: airflow obstruction, asthma, chronic obstructive pulmonary disease, pulmonary 
function test, thymic stromal lymphopoietin
Introduction
Pulmonary function is among the most important health indicators, being a strong 
predictor of long-term morbidity and mortality.1 Impaired pulmonary function is a 
strong risk factor for the development of asthma and COPD and a marker of disease 
severity. The diagnosis and assessment of COPD recommended by Global Initiative 
for Obstructive Lung Disease (GOLD) guidelines are based on the degree of airflow 
obstruction as assessed by spirometry.2 Any arbitrary classification of a continuous 
variable, such as FEV1 and the FEV1/FVC ratio, results in a group of patients with 
borderline phenotypes,3 and classification based on the FEV1 and FEV1/FVC criteria 
established by the GOLD guidelines may underemphasize the potential significance of 
the “unclassified” subgroup of individuals who have a decreased FEV1 and a normal International Journal of Chronic Obstructive Pulmonary Disease 2011:6 submit your manuscript | www.dovepress.com
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FEV1/FVC ratio. Early-life origin of COPD has recently 
been emphasized,4,5 and there is evidence that pathological 
abnormalities of COPD may be present even in the absence of 
airflow obstruction.6 However, the clinical characteristics of 
individuals with a decreased FEV1 and a normal FEV1/FVC 
ratio are not well established, and the validity of classifying 
these individuals as “normal” is uncertain.
Chronic stimulation of the innate immune system by 
microbes, inhaled allergens, or components of tobacco smoke 
is involved in the inflammation and remodeling of airways 
that underlies asthma and COPD,7,8 and certain genetic vari-
ants may play a role in the common pathogenesis of both 
asthma and COPD.9,10 TSLP is an innate cytokine released 
by primary human epithelial cells in response to certain 
microbial products, physical injury, cigarette smoke, or 
inflammatory cytokines,11,12 and TSLP has an important role 
in the initiation of allergic and adaptive airway inflamma-
tion through innate pathways that initially activate airway 
  epithelium.13 Patients with asthma have higher concentrations 
of TSLP in their lungs.14,15 Moreover, TSLP is overexpressed 
in the bronchial mucosa in patients with COPD, which 
suggests that TSLP not only plays a key role in allergic 
inflammation, but may also play a role in nonallergic airway 
inflammation.15 Our group has recently identified the TSLP 
gene as an asthma susceptibility gene.16 Since it has been 
suggested that genetic determinants of lung function influ-
ence susceptibility to asthma as well as COPD,17 our previous 
finding may indicate a role of TSLP in the development of 
airflow obstruction that originates in earlier life.
The two aims of the current study are to describe the 
characteristics of healthy subjects with lower FEV1 using a 
large dataset from healthy, non-COPD, nonasthmatic subjects 
which includes valid lung function measurements, chest 
roentgenograms, and responses about respiratory symptoms, 
and to investigate the role of functional polymorphisms at 
the TSLP gene on baseline lung function defined by FEV1% 
predicted and FEV1/FVC in these healthy subjects.
Methods
Subjects
This was a cross-sectional analysis of 1505 Japanese men and 
women aged 22 to 81 years who visited the Tsukuba Medical 
Center for annual medical checkup from June 2008 to May 
2009. Detailed information on respiratory health, lifestyle, 
and exposure conditions to environmental irritants such as 
tobacco smoking, allergens, and air pollutions was collected. 
Lung function data, chest radiographic findings, and the 
results of a standard clinical examination were also   available 
for all participants. Based on a detailed   questionnaire on 
pulmonary symptoms, a physical examination   including 
pulmonary auscultation and chest roentgenogram, we 
  carefully excluded the presence of pulmonary diseases such 
as asthma, COPD, chronic bronchitis, old tuberculosis, and 
pulmonary fibrosis.
Our diagnosis of asthma basically relied on a positive 
response to the following questions: “Have you ever been 
told by a doctor that you have asthma” and “Do you still 
have asthma?” in addition to the presence of asthmatic 
symptoms such as wheezing, cough, dyspnea, and chest 
tightness or the current use of anti-asthmatic medications. 
Chronic bronchitis was defined as self-report of cough or 
phlegm during the day or at night on most days for as much as 
3 months each year for 2 or more years. Clinical diagnosis of 
COPD was defined as reporting of any respiratory symptom 
(exertional breathlessness, chronic cough, regular sputum, 
frequent winter bronchitis, or wheeze) and evidence of air-
way obstruction on spirometry (both FEV1/FVC , 0.7 and 
FEV1 , 80% predicted). Subjects who reported previously 
doctor-diagnosed chronic bronchitis or emphysema were 
also excluded. Pulmonary tuberculosis may cause similar 
respiratory symptoms and chronic airflow limitation to those 
seen with COPD. Thus, we carefully excluded subjects with 
scarring on chest radiograph and/or previous history of 
  pulmonary tuberculosis treatment.
Classification of the subjects
Of the 1505 subjects, 113 subjects with a history of asthma, 
COPD, chronic bronchitis, interstitial pneumonia, or pul-
monary tuberculosis were excluded; 1392 (92.5%) subjects 
who had no pulmonary diseases were eligible to participate 
in the study. None of these 1392 subjects were taking bron-
chodilators such as β-agonists, anticholinergics, antileukot-
rienes, methylxanthines, or inhaled corticosteroids. Of the 
1392 subjects without respiratory diseases, 23 subjects had 
FEV1/FVC , 70%. To characterize the group of individuals 
with decreased FEV1 (predicted FEV1 , 80%) and normal 
ratio of FEV1/FVC, we divided the 1369 healthy subjects 
into 2 subgroups according to their prebronchodilator FEV1 
(% predicted): ,80% (lower FEV1, n = 217) and $80% 
(higher FEV1, n = 1152).
Of these subjects, 365 healthy subjects with normal lung 
function were used as the control group in our previous 
genetic study of TSLP for adult asthma.16 The flowchart of 
the current study is shown in Figure 1.
The Medical Ethics Committees of the University of 
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(Tsukuba, Japan) both approved the study, and each subject 
provided written informed consent.
Pulmonary function test (PFT)
Spirometry performance was required to meet the criteria 
by the Japanese Respiratory Society (JRS).18 Data for FEV1, 
FVC, and FEV1/FVC ratio were available for all participants. 
Lung function was measured in the standing position using 
an electronic spirometer (Autospiro series; Minato Medical 
Science Co., Ltd, Osaka, Japan). No bronchodilation was 
applied. Well-trained spirometry technicians continuously 
monitored the procedure and reviewed flow-volume curves 
to ensure adherence to standards. Participants performed 
up to 3 forced expiratory maneuvers to obtain acceptable 
maneuvers; FEV1 and FVC values taken to characterize 
each participant were the maximum results obtained from 
acceptable maneuvers. FEV1 and FVC were expressed as 
percentage of predicted values according to the prediction 
equations of the JRS. FEV1/FVC ratio was calculated using 
actual values. Calibration was checked weekly with a 2-L 
syringe. Calibration checks were also undertaken as specified 
by the manufacturer. All available longitudinal data of FEV1 
were collected retrospectively to evaluate the annual decline 
of FEV1 for every participant.
Genotyping
A total of 23 polymorphisms in the TSLP gene have been 
identified in the Japanese population.19 Three tag SNPs 
in TSLP, rs3806933, rs2289276, and rs2289278, were 
genotyped using the TaqMan allele-specific amplification 
method (Applied Biosystems, Foster City, CA) as described 
previously.16
Statistics
Descriptive statistics were expressed as mean ± standard 
deviation (SD). We compared clinical data – gender, age, 
body mass index (BMI), smoking habits (never smoker, 
  ex-smoker, and current smoker), smoking index, total serum 
IgE levels, atopy (defined as at least 1 positive response to 
14 inhaled antigens), and annual decline of FEV1 – between 
2 groups (the lower FEV1 group and the higher FEV1 group) 
using a 2-tailed Student’s t-test or Pearson’s   chi-square 
test as appropriate. Smoking index was calculated by 
  multiplying smoking dose (cigarettes per day) and dura-
tion (years smoked), and was categorized into 3 groups: 
0, 0 to 200, and .200 cigarette-years.
The use of a fixed threshold to define airway   obstruction is 
associated with some extent of misclassification.21 Therefore, 
in addition to the fixed values of FEV1/FVC (70%) and FEV1 
(80% of predicted), we also used the age- and   sex-specific 
lower limit of normal (LLN) as an alternative threshold for 
the FEV1/FVC ratio and FEV1 to categorize 1392 healthy 
subjects without pulmonary   diseases. We used spirometry 
reference equations for FEV1/FVC and FEV1 for men and 
women from a large Japanese population-based study (1863 
never-smoking adults from ages 18 to 95 years).22 The LLNs 
for FEV1/FVC and FEV1 were   calculated by subtracting 
1.645 × residual standard   deviation (RSD) from the predicted 
means assuming a   Gaussian distribution of the residuals.
Values of the annual decline of FEV1 were computed 
for each individual across the repeated measurements 
using a   linear mixed-effect model. We included only those 
subjects who took the annual checkup for at least 4 years 
of   retrospective follow-up and who had at least 4 separate 
PFT measurements to obtain an accurate estimate; among 
1392 healthy subjects, 866 subjects had valid estimates 
of the annual decline of FEV1. The median number of 
  measurements was 9 (range 4–18 measurements) and the 
median number of years in retrospective follow-up was 11 
(range 4–23 years) for the 866 subjects. We used a random 
intercept to take into account the heterogeneity across 
subjects and the correlation induced by having repeated 
observations on the same subjects. We chose 25 years of 
Figure 1 Recruitment and enrollment of study participants. Of the 1,505 participants, 
113  subjects  with  a  history  of  asthma,  COPD,  chronic  bronchitis,  or  pulmonary 
tuberculosis were excluded, and 4 of those excluded were identified as having 2 or 
3 pulmonary diseases. Of the 1,392 subjects without respiratory diseases, 23 subjects 
had FEV1/FVC , 70%. To characterize the group of individuals with decreased FEV1 
(predicted FEV1 , 80%) and normal ratio of FEV1/FVC, we divided 1,369 healthy 
subjects  whose  FEV1/FVC  was  $70%  into  2  subgroups  according  to  their 
prebronchodilator FEV1 (% predicted): ,80% (lower FEV1, n = 217) and $80% (higher 
FEV1, n = 1,152). We also examined the relationship between TSLP single nucleotide 
polymorphisms and baseline lung function using 1,368 healthy subjects, who agreed 
to provide a DNA sample for genotyping. Of the 1,392 healthy subjects, the median 
number of measurements was 9 (range 4–18 measurements) and the median number 
of years in retrospective follow-up was 11 (range 4–23 years) for the 866 subjects who 
had an annual checkup for 4 or more years of the retrospective follow-up and had at 
least 4 separate pulmonary function test measurements. Valid estimates of the annual 
decline of FEV1 were obtained for 849 healthy subjects with FEV1/FVC . 70% or for 
827 healthy subjects with FEV1/FVC . lower limit of normal.
1,505 participants enrolled
1,392 healthy subjects with no
pulmonary diseases
1,368 agreed to participate in the
genetic association study
217 had a FEV1%
predicted <80%
1,152 had a FEV1%
predicted ¥80%
23 had a FEV1/FVC <70%
1,369 had a FEV1/FVC ¥70%
849 were used for the estimation of FEV1 decline
113 had a pulmonary
disease
Bronchial asthma (n = 95)
COPD (n = 7)
Old tuberculosis (n = 15)International Journal of Chronic Obstructive Pulmonary Disease 2011:6
Table 1 Characteristics of the participants at baselinea
Variables FEV1% predicted ,80% 
(N = 217)
FEV1% predicted $80% 
(N = 1152)
P value
Age range (years) 51.1 ± 10.5 (25–78) 50.1 ± 9.3 (22–78) 0.20
Male sex (%) 125 (57.6) 503 (43.7) 0.0002
BMI 23.1 ± 3.2 23.0 ± 3.1 0.72
FVC (L) 2.73 ± 0.66 3.25 ± 0.77 ,0.0001
FVC% predicted (%) 84.0 ± 9.2 104.0 ± 11.5 ,0.0001
FEV1 (L) 2.18 ± 0.53 2.72 ± 0.64 ,0.0001
FEV1/FVC (%) 80.1 ± 5.5 83.8 ± 5.0 ,0.0001
Smoking habitsb (N, %) ,0.0001
  Never smokers 106 (48.8) 759 (65.9)
  Ex-smokers 59 (27.2) 245 (21.3)
  Current smokers  52 (24.0) 148 (12.8)
Smoking indexc (N, %) ,0.0001
 0 106 (48.8) 759 (65.9)
  0–200 32 (14.8) 139 (12.1)
  .200 79 (36.4) 254 (22.0)
Serum IgE (log IU/mL) 1.86 ± 0.60 1.76 ± 0.58 0.029
Atopy (%) 125 (57.6) 668 (58.0) 0.94
FEV1 decline (mL/year)d 32.3 ± 27.0 20.8 ± 25.0 ,0.0001
  Never smokers (N = 538) 32.4 ± 25.2 (N = 65)e 18.8 ± 23.1 (N = 473)f ,0.0001
  Ex- and current smokers (N = 311) 32.3 ± 28.6 (N = 73) 24.8 ± 28.2 (N = 238) 0.048
Notes: aData are presented as mean ± SD unless otherwise indicated; bSubjects were classified as never smokers, ex-smokers, or current smokers based on questionnaire 
responses; cSmoking index was calculated for current and past smokers by multiplying smoking dose (cigarettes per day) and duration (years smoked); dTo obtain an accurate 
estimate of the annual decline of FEV1, we selected only subjects who took the annual checkup for at least 4 years of retrospective follow-up and who had at least 4 separate 
pulmonary function test measurements (n = 849); eWhen FEV1 decline was compared within the lower FEV1 group (n = 138) between never smokers and ex- or current 
smokers, no difference was found (32.4 [SD 25.2] mL/year for 65 never smokers and 32.3 [28.6] mL/year for 73 current or ex-smokers, P . 0.5); fIn the higher FEV1 group 
(n = 711), a significant difference in the annual decline of FEV1 was found between never smokers and ex- or current smokers (18.8 [SD 23.1] mL/year for 473 never smokers 
and 24.8 [28.2] mL/year for 238 current or ex-smokers, P = 0.0026).
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age as the starting point for the analyses because maximum 
lung function would be achieved before that age and lung 
function is thought to be in decline by that age.20 Estimation 
of an annual decline of FEV1 was performed using SYSTAT 
software, version 13 (Systat Software, Inc., Chicago, IL). 
Valid estimates of the annual decline of FEV1 were obtained 
for 849 subjects with FEV1/FVC . 70% or for 827 subjects 
with FEV1/FVC . LLN.
General linear models were used to assess associations 
between TSLP polymorphisms and pulmonary function 
measurements after adjusting for gender, age, BMI, FVC% 
predicted, smoking status, smoking index, and total serum 
IgE levels (log-transformed). We used the Hardy-Weinberg 
equilibrium (HWE) program23 to compare observed num-
bers of genotypes with the numbers of genotypes expected 
under HWE. In the association study, we applied a Bonfer-
roni correction on the P-values. As we tested 3 polymor-
phisms, we used P = 0.05/3 = 0.0167 as a threshold for 
significance.
For haplotype analyses, we used the Haplo.score   program, 
which adjusted for covariates and calculated   simulation 
P values for each haplotype.24 P values , 0.05 were 
considered to indicate statistical significance.
Results
The characteristics of the population studied are shown in 
Table 1. The individual values of FEV1 and FEV1/FVC for 
all healthy subjects (n = 1392) are shown in Figure 2. Based 
on GOLD guidelines, 217 subjects who had a reduced FEV1 
(,80% of predicted) could not be classified as having COPD 
because they had a FEV1/FVC ratio $70%. In cross-sectional 
analyses, the percentage of males in the lower FEV1 group 
was significantly higher than the percentage of males in the 
higher FEV1 group. No significant differences in the following 
factors were observed between the 2 groups – lower FEV1 
and higher FEV1: age (range), 51.1 (25–78) vs 50.1 (22–78); 
BMI, 23.1 vs 23.0; and atopy, 57.6% vs 58.0% for the lower 
FEV1 group and the higher FEV1 group, respectively. Among 
subjects who had a normal FEV1/FVC ratio and a decreased 
FEV1% (the lower FEV1 group), 48.8% had never smoked. 
Nevertheless, smokers were more common in the lower 
FEV1 group than in the higher FEV1 group (P , 0.0001). International Journal of Chronic Obstructive Pulmonary Disease 2011:6 submit your manuscript | www.dovepress.com
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The smoking index was also significantly higher in the lower 
FEV1 group than in the higher FEV1 group (P , 0.0001). 
Levels of serum total IgE were higher in the lower FEV1 
group (P = 0.029). Annual decline of FEV1 calculated by a 
linear mixed regression averaged 32.3 mL/year for the lower 
FEV1 group and 20.8 mL/year for the higher FEV1 group 
(P , 0.0001). When FEV1 decline was compared within the 
lower FEV1 group (n = 138) between never smokers and ex- or 
current smokers, no difference was found according to smok-
ing status (32.4 [SD 25.2] mL/year for 65 never   smokers and 
32.3 [28.6] mL/year for 73 current or ex-smokers, P . 0.5). 
In contrast, in the higher FEV1 group (n = 711), a significant 
difference in the annual decline of FEV1 was found between 
never smokers and ex- or current smokers (18.8 [SD 23.1] 
mL/year for 473 never smokers and 24.8 [28.2] mL/year for 
238 current or ex-smokers, P = 0.0026).
Among 1392 healthy subjects, 866 subjects had a valid 
estimate of the annual decline in FEV1. When these 866 sub-
jects were studied, the annual decline of FEV1 between lower 
FEV1 group and higher FEV1 group was also significantly 
different irrespective of how we define the lower FEV1 groups 
(FEV1% , 80% predicted or FEV1 , LLN). In addition, 
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Figure 2 Plot of individual values of FEV1% predicted and FEV1/FVC. Data from 
1392 healthy adults with no respiratory diseases.
Table 2 Association between FEV1 and a decline of FEV1 in healthy subjects
Criteria for defining normal 
FEV1/FVC ratio
Criteria for defining 
the higher FEV1 group
Annual FEV1 declined 
(lower FEV1 group)
Annual FEV1 declined 
(higher FEV1 group)
P
FEV1/FVC $ 70% (n = 1369)a FEV1% $ 80% 32.3 ± 27.0 (n = 138) 20.8 ± 25.0 (n = 711) ,0.0001
FEV1/FVC $ LLN (n = 1331)b FEV1 $ LLN 31.1 ± 29.8 (n = 84) 21.1 ± 24.3 (n = 743) 0.0005
None (n = 1392)c FEV1% $ 80% 34.2 ± 29.3 (n = 147) 21.0 ± 25.1 (n = 719) ,0.0001
None (n = 1392)c FEV1 $ LLN 36.1 ± 34.3 (n = 106) 21.5 ± 24.5 (n = 760) ,0.0001
Notes: Valid estimates of the annual decline of FEV1 were obtained for 849,a 827,b and 866c healthy subjects, respectively; dmL/year.
Abbreviation: LLN, lower limit of normal.
when 61 healthy subjects with FEV1/FVC , LLN were 
excluded from the analysis, the annual decline in FEV1 
consistently differed between higher and lower groups, 
as the lower FEV1 group was defined using the cut-off of 
FEV1 , LLN (Table 2).
DNA for a genetic association study was available for 1368 
of the 1392 healthy subjects with no   pulmonary   diseases. All 
SNPs investigated were within HWE (P . 0.05). The   overall 
success rate for genotyping was 99.3%. The genotypic fre-
quency of TSLP gene   polymorphisms among the healthy 
Japanese participants (n = 1368) are shown in Table 3. SNP 
rs3806933 was associated with a lower FEV1% predicted 
(corrected P = 0.036) and with a lower FEV1/FVC ratio 
  (corrected P = 0.033). SNP rs2289276 was also associ-
ated with a lower FEV1/FVC (corrected P = 0.029). Both 
associations were driven by carriers of 2 minor alleles 
(recessive models); significant associations were noted with 
a lower FEV1% predicted and with a lower FEV1/FVC at 
rs3806933 (corrected P = 0.027 and corrected P = 0.015, 
respectively) and at rs2289276 (corrected P = 0.042 and 
corrected P = 0.015, respectively). In contrast, there was 
no association between the genotype at rs2289278 and the 
FEV1% predicted or the FEV1/FVC phenotype. We did not 
observe any significant association between any one of these 
SNPs and the annual decline in FEV1.
As recent studies have shown sex-specific associations 
between variants of the TSLP gene and asthma,25 levels of 
total serum IgE and specific IgE antibody toward cockroach,26 
we further conducted a sex-stratified analysis; however, we 
could not determine the sex-specific effect on these asso-
ciations (data not shown). We also did not find convincing 
evidence that the effect of TSLP genetic variants in FEV1% 
predicted or FEV1/FVC was modified by environmental 
exposure to tobacco smoke in the study population (data 
not shown).
The haplotype composed of these 3 variants was signifi-
cantly associated with FEV1/FVC, with a P value of 0.018 
from 1000 simulations of a global score test, as implemented International Journal of Chronic Obstructive Pulmonary Disease 2011:6 submit your manuscript | www.dovepress.com
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in Haplo.score.24 The haplotype most strongly associated with 
lower FEV1/FVC was rs3806933C/rs2289276C/rs2289278C 
(haplotype-specific scores = –2.79, P = 0.0018) on the basis 
of 10,000 simulations; this haplotype showed significantly 
increased promoter activity in a previous study.16 For FEV1% 
predicted, haplotype analysis did not further improve the 
significance compared with the single SNP analysis.
Discussion
We studied prebronchodilator lung function results from a 
large number of Japanese adults without pulmonary disease. 
This study showed that the group of individuals who have 
normal FEV1/FVC ratio and decreased FEV1 mainly consists 
of smokers with higher cumulative tobacco consumption. 
In addition, this group was characterized by higher levels 
of total serum IgE and an increased annual decline in FEV1. 
Furthermore, this study provided preliminary evidence 
that functional SNPs in the TSLP gene influence FEV1 and 
FEV1/FVC in healthy subjects independently of the impact 
of tobacco smoke, emphasizing a distinct role for TSLP in 
airway obstruction that is a potentially important shared risk 
factor for asthma and COPD.
Although smoking is a major, modifiable risk factor, 
nonsmokers are similarly at risk for lung function decline; 
there was no difference in the annual FEV1 decline between 
smokers (32.4 mL/year) and nonsmokers (32.3 mL/year) in 
the lower FEV1 group. In a study with 20-year follow-up, 
average decline in FEV1 of 2496 healthy adults without 
airflow obstruction was 18 mL/year,27 which is compatible 
with that of 1152 healthy adults with normal FEV1 in the 
current study. An analysis of the Framingham Offspring 
Cohort also showed that the mean FEV1 decline was 19.6 mL 
for 666 males and 17.6 mL for 912 females in healthy never 
smokers.28 In contrast, in a study of 3-year follow-up, the 
mean yearly absolute decline of FEV1 in adult patients 
with mild asthma without severe asthma-related events was 
from 27 mL to 34 mL,29 which was similar to that found in 
217 healthy adults with lower FEV1 in the current study. 
Never smokers comprise a substantial proportion of indi-
viduals with COPD, which has been associated with a prior 
diagnosis of asthma, a family history of asthma, and respi-
ratory infections in childhood.4,5,30 Therefore, our findings 
indicate that the group of healthy subjects with lower FEV1 
is a mixture of individuals who are susceptible to 1 or more 
irritants including microbial infections, allergens, or tobacco 
smoking. The lower FEV1 in otherwise healthy adults may be 
a marker for an increased FEV1 decline and an increased risk 
for chronic inflammatory lung diseases such as asthma and 
COPD, indicating the importance of recognizing decreased 
FEV1 in targeting intervention efforts among smokers and 
nonsmokers alike.
The mechanism that mediates the association of the TSLP 
gene with the lower levels of FEV1 in healthy subjects is 
not defined. The level of FEV1 at a given time point in an 
individual depends on 2 potentially independent processes: 
the maximum lung function obtained during development, 
and the rate of decline of lung function with age. Because 
we failed to see genetic effects of TSLP on the annual 
decline of FEV1, the association between basal lung function 
and TSLP genotype may be the result of abnormalities in 
Table 3 Associations between TSLP genotype at 3 single nucleotide polymorphisms (SNP) and lung function
SNP N FEV1% predicted (%)  
(95%CI)
Nominal 
P value
FEV1/FVC (%)  
(95%CI)
Nominal 
P value
rs3806933 CC 721 92.04 (91.57–92.51) 0.012a 83.29 (82.89–83.68) 0.011a
CT 526 91.15 (90.60–91.71) 82.46 (81.99–82.92)
TT 112 90.95 (89.75–92.15) 82.49 (81.48–83.49)
rs3806933 CC 721 92.04 (91.57–92.51) 0.0089a 83.29 (82.89–83.68) 0.0050a
CT + TT 638 91.12 (90.62–91.62) 82.46 (82.04–82.88)
rs2289276 CC 777 91.97 (91.52–92.43) 83.26 (82.88–83.65)
CT 488 91.13 (90.55–91.70) 0.019 82.42 (81.94–82.90) 0.0096a
TT 91 90.95 (89.61–92.29) 82.44 (81.32–83.56)
rs2289276 CC 777 91.97 (91.52–92.43) 83.26 (82.88–83.65)
CT + TT 579 91.10 (90.57–91.63) 0.014a 82.43 (81.98–82.87) 0.0049a
rs2289278 CC 844 91.38 (90.94–91.82) 82.73 (82.36–83.10)
CG 466 91.97 (91.38–92.56) NSb 83.21 (82.72–83.71) NS
GG 52 92.22 (90.44–93.99) 82.80 (81.32–84.28)
rs2289278 CC 844 91.38 (90.94–91,82) NS 82.73 (82.36–83.10) NS
CG + GG 518 91.99 (91.43–92.56) 83.17 (82.70–83.64)
Notes: aP , 0.05 after Bonferroni correction; bNS, not significant; some subjects could not be genotyped for technical reasons.International Journal of Chronic Obstructive Pulmonary Disease 2011:6 submit your manuscript | www.dovepress.com
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lung development, rather than accelerated decline of lung 
  function. TSLP is released predominantly by bronchial 
epithelial and smooth muscle cells in response to certain 
microbial products,   allergen-associated molecules, tobacco 
smoke, physical injury, or inflammatory cytokines.11,31 TSLP 
integrates environmental stresses with an initial activation 
of resident innate immune cells, followed by activation 
of the adaptive immune system. Having a predisposition 
toward exaggerated TSLP responses against innocuous 
environmental antigens, individuals with particular TSLP 
genotypes would be expected to have impaired lung develop-
ment which could lead to increased susceptibility to altered 
lung functions as adults.
Significant associations of an altered lung function in 
healthy subjects were obtained with the same TSLP SNPs, 
rs3806933 (–847C/T) and rs2289276 (–82C/T), which were 
associated with asthma susceptibility in our previous study;16 
the same alleles were associated with both asthma and lower 
FEV1 in non-COPD nonasthmatic subjects. The rs3806933 
site is in the promoter region of the TSLP gene, and the minor 
allele has been shown to create a binding site for the transcrip-
tion factor activating protein (AP)-1. The   variant enhances 
AP-1 binding to the regulatory element and increases 
promoter-reporter activity of TSLP in response to poly(I:C) 
stimulation in normal human bronchial   epithelium.19 
AP-2α protein, a possible transcriptional repressor, binds 
to sequences containing the rs2289276 (–82C/T) SNP with 
a higher affinity to –82C (on the protective allele).16 Our 
  previous and current findings are consistent with a detrimen-
tal role of increased TSLP expression in pulmonary function 
and the pathogenesis of chronic inflammatory lung diseases. 
However, there remains a possibility that functional SNPs, 
other than rs3806933 and rs2289276, which are in linkage 
disequilibrium with either or both rs3806933 and rs2289276, 
may be truly responsible for our findings.
Recently, 2 studies have reported genome-wide asso-
ciation studies for lung function, using cross-sectional 
spirometric measurements in healthy individuals.32,33 They 
identified 6 genetic loci newly associated with natural varia-
tion in lung function, and it has been suggested that genetic 
determinants of lung function influence susceptibility to 
asthma and COPD. However, the list of the top 2000 SNPs 
associated with FEV1 and FEV1/FVC in these studies did not 
include any SNPs that are located in and around the TSLP 
gene including 3 SNPs examined in the current study. Failure 
to observe a SNP-for-SNP replication in ethnically diverse 
populations is not uncommon, and can result from a variation 
in allele frequencies, population admixture, heterogeneity of 
the phenotype, and environmental factors.
Our  study  has  several  limitations  that  require 
  discussion. Importantly, we do not have information about 
  postbronchodilator FEV1 for these subjects. For the clinical 
identification of early stages of COPD, the GOLD provided 
an international standard for diagnosis based on FEV1/FVC 
ratio ,0.70 measured by postbronchodilator spirometry,2 
and the use of prebronchodilator measurements prevents the 
identification of reversible obstruction. Reversible obstruc-
tions, however, are mostly undiagnosed asthma, and in this 
study, we carefully excluded asthma by a detailed question-
naire on pulmonary symptoms (cough, sputum, exertional 
dyspnea, wheeze), and physical examinations including 
pulmonary auscultation. In addition, prebronchodilator lung 
function has been used in many epidemiological studies and 
has been shown to have value in predicting health outcomes 
on a population level.5,21,34
Another limitation of our study is the retrospective nature 
of the FEV1 follow-up. The follow-up periods and numbers 
of spirometry measurements varied among subjects. This 
variation may have contributed to a biased estimation of the 
annual decline in FEV1 among subjects; however, we used a 
linear mixed-effects model to control for correlations among 
repeated measures within each subject, and we limited the 
analysis to include only subjects who had at least 4 separate 
FEV1 measurements during 4 or more years follow-up. 
Nonetheless, our results will need to be replicated in other, 
ideally prospective, studies with large cohorts.
Third, it is unclear whether the excess decline in FEV1 
found in this study led to significantly more asthma or 
COPD development. However, it is important to recognize 
that excess decline of 10 to 15 mL/year in the lower FEV1 
group compared with the higher FEV1 group would lead to 
an excess loss of 200 to 300 mL in 20 years, which would be 
expected to affect COPD incidence, particularly in subjects 
whose baseline lung function is lower. Serial measurements 
of FEV1 can presumably identify COPD at a point in time 
where the impact of the disease is generally limited. Our study 
suggests that prebronchodilator FEV1 may be a good marker 
of disease susceptibility even when the subjects have a normal 
FEV1/FVC ratio, allowing much earlier detection of COPD. 
Further prospective studies will determine whether lower 
FEV1 in healthy subjects without pulmonary diseases is asso-
ciated with the future development of asthma or COPD.
In conclusion, although the FEV1/FVC ratio is a relatively 
sensitive index of mild airflow obstruction, it seems that International Journal of Chronic Obstructive Pulmonary Disease 2011:6 submit your manuscript | www.dovepress.com
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lower FEV1 in non-COPD, nonasthmatic subjects may be 
of some help in identifying subjects at risk for these chronic 
inflammatory pulmonary diseases. Given the increasing 
societal burden of airflow obstruction, early detection of an 
altered lung function in asymptomatic adults is important. 
The demonstration of increased annual decline of FEV1, even 
in healthy adults with lower FEV1, should alert clinicians to 
the importance of case detection in subjects at risk, irrespec-
tive of their smoking status. This study may suggest the need 
for a definition of COPD that is not exclusively based on 
spirometry. In addition, we identified TSLP as associated with 
natural variation in lung function, bringing new insight into 
our understanding of the genetic basis of lung development 
and related airway disorders, such as asthma and COPD.
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